Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement

Abstract

The safety and efficacy of combined low dose aspirin and warfarin therapy in patients with atrial fibrillation after mechanical heart valve replacement were evaluated. A total of 1016 patients (620 females, mean age of 36.8±7.7 years) admitted for cardiac valve replacement and complicated with atrial fibrillation after surgery were randomly divided into study (warfarin plus 75–100 mg aspirin) or control (warfarin only) groups. International normalized ratio (INR) and prothrombin time were maintained at 1.8–2.5 and 1.5–2.0 times the normal values, respectively. Thromboembolic events and major bleedings were registered during the follow-up period. Patients were followed up for 24±9 months. The average dose of warfarin in the study and control groups was 2.91±0.83 mg and 2.88±0.76 mg, respectively (P>0.05). The incidence of overall thromboembolic events in study group was lower than that in control group (2.16% vs. 4.35%, P=0.049). No statistically significant differences were found in hemorrhage events (3.53% vs. 3.95%, P=0.722) or mortality (0.20% vs. 0.40%, P=0.559) between the two groups. Combined low dose aspirin and warfarin therapy in the patients with atrial fibrillation following mechanical heart valve replacement significantly decreased thromboembolic events as compared with warfarin therapy alone. This combined treatment was not associated with an increase in the risk of major bleeding or mortality.

Keywords

anticoagulation / mechanical valve replacement / atrial fibrillation / aspirin / warfarin

References

[1] FusterV, RydénLE, CannomDS, et al. . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 2011, 123(10): e269-367 PMID: 21382897

[2] PetersenP. Thromboembolic complications in atrial fibrillation. Stroke, 1990, 21(1): 4-13 PMID: 2405547

[3] BonowRO, CarabelloBA, ChatterjeeK, et al. . ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 2006, 48(3): e1-e148 PMID: 16875962

[4] HeringD, PiperC, BergemannR, et al. . Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German experience with low-intensity anticoagulation study. Chest, 2005, 127(1): 53-59 PMID: 15653962

[5] EdmundsLHJr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg, 1987, 44(4): 430-450 PMID: 3310938

[6] RussoA, GrigioniF, AvierinosJF, et al. . Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol, 2008, 51(12): 1203-1211 PMID: 18355659

[7] SunJC1, DavidsonMJ, LamyA, et al. . Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet, 2009, 374(9689): 565-576 PMID: 19683642

[8] HartRG, PearceLA, AguilarMI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146(12): 857-867 PMID: 17577005

[9] GoldsteinLB, AdamsR, AlbertsMJ, et al. . Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37(6): 1583-1633 PMID: 16675728

[10] ChesebroJH, FusterV, ElvebackLR, et al. . Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol, 1983, 51(9): 1537-1541 PMID: 6342354

[11] YouJH, ChanFW, WongRS, et al. . Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol, 2005, 59(5): 582-587 PMCID: 1884850 PMID: 15842557

[12] ZhangH, ChenXJ, ZhenRL, et al. . Antithrombotic effect of warfarin with different anticoagulation intensities on prognosis of old patients with paroxysmal atrial fibrillation. Chin J Geriatr Heart Brain Vessel Dis (Chinese), 2009, 11(10): 758-761

[13] MenkeJ, LüthjeL, KastrupA, et al. . Thromboembolism in atrial fibrillation. Am J Cardiol, 2010, 105(4): 502-510 PMID: 20152245

[14] HolmesDRJr, KereiakesDJ, KleimanNS, et al. . Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol, 2009, 54(2): 95-109 PMID: 19573725

[15] BassandJP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace, 2012, 14(3): 312-324 PMCID: 3283221 PMID: 22355190

[16] HennekensCH, DykenML, FusterV. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 1997, 96(8): 2751-2753 PMID: 9355934

[17] Antithrombotic Trialists’ ATT CollaborationBaigentC, BlackwellL, et al. . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009, 373(9678): 1849-1860 PMID: 19482214

[18] US Preventive Services Task Force.CalongerN, PetittiDB, et al. . Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2009, 150(6): 396-404

[19] MasselDR, LittleSH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev, 2013CD003464

[20] TurpieAG, GentM, LaupacisA, et al. . A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med, 1993, 329(8): 524-529 PMID: 8336751

[21] CappelleriJC, FioreLD, BrophyMT, et al. . Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. Am Heart J, 1995, 130(3Pt1): 547-552 PMID: 7661074

[22] LarsonRJ, FisherES. Should aspirin be continued in patients started on warfarin?. J Gen Intern Med, 2004, 19(8): 879-886 PMCID: 1492499 PMID: 15242475

[23] DentaliF, DouketisJD, LimW, et al. . Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med, 2007, 167(2): 117-124 PMID: 17242311

[24] BrtkoM, DusekJ. Antithrombotic therapy in patients after valve surgery with special attention to the combination of anticoagulant and antiplatelet therapy. Thrombosis, 2013, 55(2): e164-e169

[25] BerkowitzSD. Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. Am Heart J, 2001, 142(1): 7-13 PMID: 11431650

[26] MasselD, LittleSH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol, 2001, 37(2): 569-578 PMID: 11216981